The National Renal Complement Therapeutics Centre (NRCTC) opened in 2016. We specialise in Atypical Haemolytic Uraemic Syndrome (aHUS), Eculizumab, C3 Glomerulopathy (C3G) and MPGN.


>> Find out more

Atypical Haemolytic Uraemic Syndrome (aHUS) & Eculizumab Specialists

NRCTC specialises in Atypical Haemolytic Uraemic Syndrome (aHUS), Eculizumab, C3 Glomerulopathy (C3G) and MPGN.

Members of our team have been instrumental in research into pathogenic mechanisms of aHUS that has revealed the important role of complement.

Approximately 50% of patients with aHUS have an underlying complement abnormality. Eculizumab is a complement inhibitor that was recommended by NICE in the treatment of aHUS in England.

Eculizumab is currently funded by NHS England through the national aHUS service based within the National Renal Complement Therapeutics Service at the Newcastle upon Tyne Hospitals NHS Foundation Trust.

Learn More